SCHEMBL27218766

SCHEMBL27218766

COc1ccc(-c2noc(CSc3nnc4[nH]cnn34)n2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 13/20 0.63
TNKS O95271 5/20 0.63
CYP3A4 P08684 3/20 0.63
CYP2C9 P11712 3/20 0.63
AXIN2 Q9Y2T1 3/20 0.63
MAPT P10636 7/20 0.60
THRB P10828 3/20 0.60
TP53 P04637 7/20 0.59
SMN1; SMN2 Q16637 2/20 0.56
ALDH1A1 P00352 2/20 0.54
HTT P42858 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
CYP2D6 P10635 1/20 0.54
SULT2A1 Q06520 1/20 0.54
NR5A1 Q13285 1/20 0.54
MEN1 O00255 1/20 0.51
USP2 O75604 1/20 0.51
LMNA P02545 1/20 0.51
KMT2A Q03164 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16447499 0.78 TNKS2 (1.00) TNKS2TNKSCYP3A4CYP2C9AXIN2
SCHEMBL11919921 0.72 TNKS2 (0.76) TNKS2TNKSCYP3A4CYP2C9AXIN2
SCHEMBL11919898 0.70 TNKS2 (1.00) TNKS2TNKSCYP3A4CYP2C9AXIN2
SCHEMBL14788168 0.69 SIRT2 (0.74) MAPTTHRBSMN1; SMN2ALDH1A1HTT
SCHEMBL11919903 0.69 TP53 (1.00) TNKS2TNKSCYP3A4CYP2C9AXIN2
SCHEMBL11919906 0.69 TP53 (0.82) TNKS2TNKSCYP3A4CYP2C9AXIN2
SCHEMBL27218866 0.68 MAPT (0.58) TNKS2TNKSCYP3A4CYP2C9AXIN2
SCHEMBL16010756 0.68 TNKS2 (1.00) TNKS2TNKSCYP3A4CYP2C9AXIN2
SCHEMBL17513948 0.67 SIRT2 (0.65) MAPTTHRBSMN1; SMN2ALDH1A1HTT
SCHEMBL1220782 0.67 SMN1; SMN2 (0.66) MAPTTHRBSMN1; SMN2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 TNKS2 4042/4885TNKS 4259/4885CYP3A4 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.